ReCand
Pre-clinical- Indications
- Fungal detection
Company intelligence / Profile preview
Santa Fe BioLabs has developed proprietary culture media and assays—ReCand and AuriFind—for the optimized recovery, identification, and selective growth of viable Candida auris from environmental or clinical samples. These tools address shortcomings in conventional methods by improving sensitivity for dry-stressed cells. The company holds patents on these technologies. Their products are intended to help prevent outbreaks of this dangerous yeast in healthcare settings.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Santa Fe BioLabs.